TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3308483
Drug: Alternating combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating combinations of two three-drug regimens (Regimen A: vincristine 1.5 mg, adriamycin 70 mg, methotrexate 50 mg; Regimen B: 5-fluorouracil 750 mg, vindesine 5 mg intravenously, cyclophosphamide 50 mg orally, followed by three doses of cyclophosphamide 50 mg at 6-h intervals)
Study: 3308483
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (single and alternating combinations)
Study: 15170011
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with single dose (2 g) metronidazole and clotrimazole cream for 3 days, randomized to follow-up strategies
Study: 15170011
Drug: Follow-up strategy
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up strategy B: Come back on day 7 regardless of response to treatment
Study: 9660431
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg every 28 days IM) + placebo tablets (group A)
Study: 9660431
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg every 28 days IM) + 2.5 mg of tibolone per os (group B)
Study: 7640448
Drug: Prophylactic portal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic portal infusion chemotherapy (PPIC)
Study: 782700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone
Study: 782700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)
Study: 21862829
Drug: Opioid blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid blockade (8 mg of naloxone)
Study: 19696704
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg oral transmucosal fentanyl citrate
Study: 9766793
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (40 IU kg(‐1)i.v., three times weekly)
Study: 6179
Drug: Practolol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (250 mg)
Study: 6179
Drug: Tolamolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol (100 mg)
Study: 6179
Drug: Tolamolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol (200 mg)
Study: 10479194
Drug: 6.6 g
Normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 g n‐3 PUFA
Study: 10479194
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g n‐3 PUFA
Study: 1649840
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of estrogen alone
Study: 1649840
Drug: Percutaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous administration of estrogen
Study: 1649840
Drug: Utrogestan in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan in combination with oral estrogen
Study: 6359083
Drug: Propiram fumarate
Normalized name: fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiram fumarate 50 mg
Study: 354840
Drug: Codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine sulfate 60 mg
Study: 30262155
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with T4 normalization after 5 months (median and percentiles 2.0-10.5 months)
Study: 14595048
Drug: Diphtheria-tetanus-acellular pertussis
Normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)
Study: 14595048
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine only (DT)
Study: 8804804
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms oral misoprostol
Study: 1615883
Drug: dF 15
Normalized name: Adriamycin RDF 150mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF 15 mg twice daily for 26 weeks
Study: 6151206
Drug: Divided dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dosage (DD) of prazepam 40 mg per day (10 mg in the morning, 10 mg at noon, 20 mg in the evening)
Study: 6151206
Drug: Single dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage (SD) of prazepam 40 mg per day (40 mg in the evening)
Study: 29738057
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 30 mL 0.25% levobupivacaine
Study: 29738057
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration with 20 mL of levobupivacaine 0.5%
Study: 21034545
Drug: Vital capacity
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital capacity induction with 8% sevoflurane at 6 L/min
Study: 21034545
Drug: Tidal breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal breathing induction with 8% sevoflurane at 6 L/min
Study: 1792400
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg
Study: 1968919
Drug: Cetirizine 20
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 20 mg (three daily doses)
Study: 1968919
Drug: Cetirizine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (5, 10, and 20 mg)
Study: 1968919
Drug: Cetirizine and
Normalized name: Cetirizine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine and Albuterol
Study: 1968919
Drug: Albuterol 4
Normalized name: albuterol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 4 mg
Study: 395955
Drug: Nicergoline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (3 x 1 dragée at 10 mg for 12 weeks)
Study: 30288999
Drug: automated closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: automated closed-loop therapy
Study: 30288999
Drug: sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: sensor-augmented pump therapy
Study: 20965155
Drug: Length of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Length of hormone therapy (HT) use
Study: 2882420
Drug: Coronary‐artery bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary‐artery bypass surgery plus medical therapy
Study: 26545320
Drug: Antiplatelet or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet or anticoagulant drugs
Study: 26545320
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet or anticoagulant drugs
Study: 20128041
Drug: Feiji Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feiji Recipe combined with chemotherapy
Study: 20128041
Drug: Chemotherapy (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinorelbine plus cisplatin or gemcitabine plus cisplatin)
Study: 16417182
Drug: Montelukast added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast added to previous medication for asthma treatment (4 weeks duration)
Study: 16417182
Drug: Montelukast added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast added to previous medication for asthma treatment (8 weeks duration)
Study: 7550184
Drug: Oral bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromfenac
Study: 1709239
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 0.1 nmol kg‐1 min‐1 (ADR‐L, n=8)
Study: 1709239
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 0.4 nmol kg‐1 min‐1 (ADR‐H, n=7)
Study: 1709239
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (placebo, n=10)
Study: 26343550
Drug: Glucagon 0.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon 0.11 to 0.44 mg and 0.33, 0.66 and 1 mg
Study: 18606439
Drug: NAC (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (neoadjuvant chemotherapy) followed by surgery
Study: 12114362
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin (TOBI), 300 mg, delivered by nebulizer, twice daily, in three 28-day on/28-day off treatment cycles
Study: 7668873
Drug: Granisetron combined
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron combined with other antiemetic drugs
Study: 2205418
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment with intravenous streptokinase
Study: 2205418
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment with intravenous streptokinase within 3 hours of onset of symptoms
Study: 27445266
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels <2.5 g/L
Study: 22147444
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (maintenance or increase in immunosuppressive therapy)
Study: 11318254
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied three times a week
Study: 11318254
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied once daily
Study: 11318254
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied twice daily
Study: 11318254
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied three times a day
Study: 11318254
Drug: Increased dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosing frequency (from three times a week to three times a day)
Study: 9137677
Drug: Cibenzoline (221
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (221 ± 60 mg daily)
Study: 9137677
Drug: Flecainide (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (165 ± 49 mg daily)
Study: 7955972
Drug: Islet cell
Normalized name: Islet cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet cell antibodies (ICA) testing in previous GDM patients
Study: 7955972
Drug: Islet cell
Normalized name: Islet cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet cell antibodies (ICA) positivity
Study: 7955972
Drug: Insulin autoantibodies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin autoantibodies (IAA) testing
Study: 3555788
Drug: DAT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAT regimen (daunorubicin 70 mg/m2/day on Days 1‐3, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Study: 3555788
Drug: TAD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD regimen (daunorubicin 70 mg/m2/day on Days 5‐7, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Study: 28425747
Drug: 10-session psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session psychiatric treatment augmented with the responsive intervention of the motive-oriented therapeutic relationship
Study: 28425747
Drug: 10-session psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session psychiatric treatment
Study: 23410714
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel implant (ENG-I)
Study: 16648503
Drug: Irinotecan 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 65 mg/m2 IV + cisplatin 30 mg/m2 IV on days 1 and 8 every 21 days
Study: 16648503
Drug: Etoposide 120
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 120 mg/m2 IV on days 1 to 3 + cisplatin 60 mg/m2 IV on day 1 every 21 days
Study: 8809212
Drug: Nitroglycerine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine administered sublingually
Study: 1534248
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA)
Study: 1534248
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with HD-MPA
Study: 30823952
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid combined with tiotropium bromide
Study: 21631592
Drug: Implant-supported overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported overdentures (IOD)
Study: 21631592
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed dental prostheses (IFDP)
Study: 21631592
Drug: Implant-supported prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported prostheses (C/IOD and IFDP/IFDP)
Study: 17659490
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy (IPT) plus medication
Study: 17659490
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus Clinical Management
Study: 7682927
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 or 50 mg)
Study: 3551051
Drug: Pankreon granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pankreon granules 20 g per day
Study: 30174101
Drug: IANB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB with intraligamentary injection
Study: 30174101
Drug: IANB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB with buccal injection
Study: 23636182
Drug: Bone cement
Normalized name: bone cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone cement without antibiotic (control group)
Study: 19289931
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or chemotherapy and radiotherapy combination
Study: 15090880
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis within 3 hours
Study: 15090880
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis beyond 3 hours with improved selection criteria
Study: 11495257
Drug: Rifampicin in
Normalized name: Product containing rifampicin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin in fixed-dose combination (FDC) anti-tuberculosis formulations
Study: 11495257
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion data
Study: 9265935
Drug: Thiopental at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental at 10 micrograms/ml
Study: 9265935
Drug: Thiopental at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental at 5 and 7.5 micrograms/ml
Study: 8102107
Drug: HEEH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEEH and drugs
Study: 8102107
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet (ED) therapy (more than 30 kcal/kg ideal body weight/day)
Study: 3524428
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g every 8 h)
Study: 3524428
Drug: Cefamandole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (2 g every 6 h)
Study: 3524428
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g every 12 h)
Study: 27657520
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI 90 μg
Study: 27523719
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI 180 μg
Study: 27523719
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA 180 μg
Study: 27657520
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA 90 μg
Study: 19260368
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and rectal non-steroidal pain-killers
Study: 15915011
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg inhaled via HFA-134a inhaler (Modulite HFA)
Study: 12891190
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy (administered immediately at local hospitals)
Study: 10574676
Drug: Preresectional chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preresectional chemotherapy with mitomycin 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2, given intravenously on day 1 of each cycle at 3-week intervals followed by surgery.
Study: 1761240
Drug: Gynatren (lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynatren (lactobacillus vaccine)
Study: 6282542
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg at bedtime
Study: 24509938
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel applied to the wound after stitch-out for 1 month
Study: 17096458
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment assignment
Study: 9659862
Drug: Guided self-change
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavior therapy)
Study: 9659862
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (16 sessions of weekly cognitive behavior therapy)
Study: 2540724
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lithium carbonate and imipramine hydrochloride
Study: 19510
Drug: Butaclamol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butaclamol (up to 50 mg/day)
Study: 19510
Drug: Butaclamol (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butaclamol (maintenance dose of 5 to 20 mg/day)
Study: 25001274
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg and 80 mg
Study: 16809729
Drug: Alfimeprase 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfimeprase 3.0 mg
Study: 16809729
Drug: Alfimeprase 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfimeprase 1.0 mg
Study: 16809729
Drug: Alfimeprase 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfimeprase 0.3 mg
Study: 16809729
Drug: Alteplase 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 2.0 mg
Study: 14663215
Drug: Hydrocortisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (25 mg)
Study: 10800630
Drug: Tetrazepam-ratiopharm film-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrazepam-ratiopharm film-coated tablets (test preparation)
Study: 10800630
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of a reference preparation (reference preparation)
Study: 8653995
Drug: Thioridazine 100
Normalized name: thioridazine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 100 mg for 14 days
Study: 1458567
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) at 330 mg/m2 per week for colorectal cancer (167 mg/m2 daily for the first 3 months), Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks for gastric cancer. 5-FU at 1,000 mg/m2 every week for 19 colorectal cancer patients.
Study: 1458567
Drug: Implantable port
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable port system for repeated hepatic arterial infusion chemotherapy.
Study: 17542340
Drug: C.E.R.A. (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. (all doses)
Study: 14716711
Drug: Risperidone monotherapy
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone monotherapy (4.2 mg/day)
Study: 11826488
Drug: Nitrullin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrullin in combination with VPN
Study: 9552059
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methotrexate with folinic acid rescue and continuing intrathecal methotrexate (HDMTX)
Study: 9552059
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (ITMTX, HDMTX, CRTX)